Great West Life Assurance CO Supernus Pharmaceuticals, Inc. Transaction History

Great West Life Assurance CO

  • $57.4 Billion
  • Q3 2024

A detailed history of Great West Life Assurance CO transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 69,802 shares of SUPN stock, worth $2.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69,802
Previous 66,516 4.94%
Holding current value
$2.79 Million
Previous $1.78 Million 22.37%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$25.77 - $35.16 $84,680 - $115,535
3,286 Added 4.94%
69,802 $2.18 Million
Q2 2024

Aug 12, 2024
BUY
$25.99 - $33.85 $313,829 - $408,738
12,075 Added 22.18%
66,516 $1.78 Million
Q1 2024

May 13, 2024
BUY
$27.11 - $35.17 $298,725 - $387,538
11,019 Added 25.38%
54,441 $1.85 Million
Q4 2023

Feb 13, 2024
SELL
$22.72 - $29.68 $62,457 - $81,590
-2,749 Reduced 5.95%
43,422 $1.25 Million
Q3 2023

Nov 14, 2023
SELL
$27.57 - $32.91 $37,329 - $44,560
-1,354 Reduced 2.85%
46,171 $1.27 Million
Q2 2023

Aug 10, 2023
SELL
$29.91 - $38.73 $127,954 - $165,686
-4,278 Reduced 8.26%
47,525 $1.43 Million
Q1 2023

May 12, 2023
SELL
$34.93 - $42.03 $117,783 - $141,725
-3,372 Reduced 6.11%
51,803 $1.88 Million
Q4 2022

Feb 10, 2023
SELL
$31.09 - $37.88 $133,562 - $162,732
-4,296 Reduced 7.22%
55,175 $1.97 Million
Q3 2022

Nov 01, 2022
BUY
$28.79 - $35.41 $189,495 - $233,068
6,582 Added 12.44%
59,471 $2.01 Million
Q2 2022

Aug 12, 2022
BUY
$25.33 - $34.25 $1.34 Million - $1.81 Million
52,889 New
52,889 $1.53 Million
Q2 2022

Aug 09, 2022
SELL
$25.33 - $34.25 $1.16 Million - $1.57 Million
-45,859 Closed
0 $0
Q1 2022

May 12, 2022
BUY
$28.51 - $32.9 $8,239 - $9,508
289 Added 0.63%
45,859 $1.52 Million
Q4 2021

Feb 14, 2022
BUY
$26.37 - $34.22 $8,016 - $10,402
304 Added 0.67%
45,570 $1.33 Million
Q2 2021

Aug 11, 2021
SELL
$26.72 - $33.19 $22,872 - $28,410
-856 Reduced 1.86%
45,266 $1.39 Million
Q1 2021

May 17, 2021
SELL
$24.15 - $31.45 $144,851 - $188,637
-5,998 Reduced 11.51%
46,122 $1.21 Million
Q4 2020

Feb 16, 2021
SELL
$17.7 - $25.81 $113,846 - $166,009
-6,432 Reduced 10.99%
52,120 $1.31 Million
Q3 2020

Nov 17, 2020
BUY
$20.2 - $25.05 $636,380 - $789,175
31,504 Added 116.47%
58,552 $1.22 Million
Q3 2020

Nov 13, 2020
SELL
$20.2 - $25.05 $761,944 - $944,886
-37,720 Reduced 58.24%
27,048 $563,000
Q2 2020

Aug 17, 2020
SELL
$17.09 - $24.89 $90,901 - $132,389
-5,319 Reduced 7.59%
64,768 $1.54 Million
Q1 2020

May 14, 2020
BUY
$14.45 - $24.69 $98,245 - $167,867
6,799 Added 10.74%
70,087 $1.26 Million
Q4 2019

Feb 11, 2020
BUY
$19.93 - $29.13 $1.26 Million - $1.84 Million
63,288 New
63,288 $1.5 Million
Q3 2019

Oct 25, 2019
SELL
$25.47 - $33.37 $1.78 Million - $2.33 Million
-69,919 Closed
0 $0
Q2 2019

Jul 31, 2019
SELL
$29.96 - $38.87 $7,370 - $9,562
-246 Reduced 0.35%
69,919 $0
Q1 2019

May 08, 2019
BUY
$32.77 - $41.99 $65,540 - $83,980
2,000 Added 2.93%
70,165 $2.46 Million
Q4 2018

Feb 12, 2019
BUY
$30.84 - $49.51 $109,142 - $175,215
3,539 Added 5.48%
68,165 $2.09 Million
Q3 2018

Nov 13, 2018
SELL
$42.7 - $56.55 $94,665 - $125,371
-2,217 Reduced 3.32%
64,626 $3.25 Million
Q1 2018

May 10, 2018
SELL
$37.15 - $46.9 $5,201 - $6,566
-140 Reduced 0.21%
66,843 $3.06 Million
Q4 2017

Feb 09, 2018
SELL
$36.4 - $42.6 $61,006 - $71,397
-1,676 Reduced 2.44%
66,983 $2.67 Million
Q3 2017

Nov 09, 2017
BUY
$36.75 - $49.65 $2.52 Million - $3.41 Million
68,659
68,659 $2.7 Million

Others Institutions Holding SUPN

# of Institutions
287
Shares Held
60.6M
Call Options Held
27.7K
Put Options Held
11.3K
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.14B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email